Skip to main content

18 publications

Name Date Type Actions

SALES 1st quarter 2024: €134M

The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.

Public releases

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

Public releases

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

Public releases

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

Public releases

Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement

December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China.

Public releases

Q3 2019 sales: €100.2 million (Up 11.0%)

The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year.

Public releases

[AUDIO] Présentation des résultats semestriels 2019 - french

Vetoquinol - 25.07.2019 - Enregistrement Audio Conference

Half Year Report

2019 Half year Financial Report (french)

Half year Financial Report

Half Year Report

H1 2019 RESULTS

H1 2019 results

 

Half Year Report

First half 2019 results

At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements.

Public releases